secwatch.observer — SEC 8-K summary
======================================

Issuer:     Olema Pharmaceuticals, Inc. (OLMA)
CIK:        0001750284
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0001558370-23-013927
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Olema reports Q2 net loss $20.1M; cash $167.4M; Phase 3 trial on track Q4 2023
------------------------------------------------------------------------------

- Net loss $20.1M for Q2 2023, down from $32.9M in Q2 2022; R&D expenses $18.0M.
- Cash, cash equivalents and marketable securities $167.4M as of June 30, 2023, funding operations into Q2 2025.
- OPERA-01 pivotal Phase 3 trial of palazestrant (OP-1250) monotherapy to enroll first patient in Q4 2023.
- Palazestrant Phase 2 monotherapy data as oral presentation at ESMO Congress October 22, 2023.
- Interim Phase 1b/2 combination data with CDK4/6 inhibitors to be presented in Q4 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1750284/000155837023013927/0001558370-23-013927-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1750284/000155837023013927/olma-20230808x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-013927

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer